Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
The U.S. Centers for Disease Control and Prevention is working with public-health officials in Alabama to probe the…
Quest Diagnostics’ COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance
Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of…
UPDATE: CureVac, GlaxoSmithKline Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study (Body Of This Headline Contains Contents Of Press Release)
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
- Demonstrated neutralizing capacity against the Omicron variant in vaccinated
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
Sierra Oncology Stock Is Soaring: Here’s Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total…
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for…
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.
Why Did FDA Pull Authorization For GSK-Vir’s COVID-19 Therapy? Read Here
The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc’s (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment.…